Skip to main content
All Posts By

Andy

Virginia Tech Hokies logo

VA Tech Research: Words activate hidden brain processes shaping emotions, decisions, and behavior

By News

Virginia Tech Hokies logoIn an unprecedented new study in the journal Cell Reports, researchers have shown neurotransmitters in the human brain are released during the processing of the emotional content of language, providing new insights into how people interpret the significance of words.

The work, conducted by an international team led by Virginia Tech scientists, offers deeper understanding into how language influences human choices and mental health.

Spearheaded by computational neuroscientist Read Montague, professor of the Fralin Biomedical Research Institute at VTC and director of the institute’s Center for Human Neuroscience Research, the study represents a first-of-its-kind exploration of how neurotransmitters process the emotional content of language — a uniquely human function.

Read More
IONQ Logo

State of Maryland, University of Maryland Announce $1 Billion “Capital of Quantum” Initiative

By News

IONQ LogoCOLLEGE PARK, Md., January 14, 2025–(BUSINESS WIRE)–IonQ (NYSE: IONQ), a leader in the quantum computing and networking industries, today announced a landmark partnership with the University of Maryland and the State of Maryland with the aim to establish Maryland as the “silicon valley” of the quantum computing industry. The proposed initiative will aim to fuel the growing quantum economy of the U.S. capitol region, provide access to IonQ’s cutting-edge quantum technology, and dramatically strengthen Maryland’s workforce with new quantum-focused jobs.

As part of today’s announcement of the “Capital of Quantum” initiative’s goal of catalyzing more than $1 billion in investments towards Maryland becoming the “Capital of Quantum,” IonQ intends to anchor a state-of-the-art quantum intelligence campus based at the University of Maryland at College Park.

Read More
Emergent

Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals

By News

EmergentGAITHERSBURG, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma Pharmaceuticals’ KLOXXADO® (naloxone HCl) Nasal Spray, an 8 mg naloxone agent that is approved for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.1 This six-year agreement complements and strengthens Emergent’s mission to protect, enhance, and save lives by helping to reduce opioid overdose deaths —providing compelling product options, combined with a commitment to increasing naloxone access, awareness, and education.

Read More
AbbvieRegen

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program

By News

NORTH CHICAGO, Ill. and ROCKVILLE, Md.Jan. 13, 2025 /PRNewswire/ — AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical AbbvieRegenprogram.

ABBV-RGX-314 in Wet Age-Related Macular Degeneration (wet AMD), Subretinal Delivery
Data from the ATMOSPHERE® and ASCENT™ pivotal trials evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet AMD are expected in 2026.

ABBV-RGX-314 in Diabetic Retinopathy (DR), Suprachoroidal Delivery
AbbVie and REGENXBIO will plan a Phase 3 clinical program. The clinical program will utilize the in-office SCS Microinjector® to deliver gene therapy to the suprachoroidal space of the eye.

Read More
Novavax Logo

Novavax is Powering the Future of Vaccines Through R&D and Value-creating Business Strategy

By News
Novavax LogoJanuary 13, 2025 – By Ruxandra Draghia-Akli, MD, PhD, Executive Vice President, Head of R&D and Elaine O’Hara, Executive Vice President, Chief Strategy Officer

As we enter the new year, Novavax is embarking on an ambitious new corporate growth strategy to maximize the impact of our cutting-edge technology. We are focused on forging strategic partnerships for both our early- and late-stage research and development (R&D) assets and our Matrix-M™ adjuvant with the goal of driving vaccine innovation that protects the health of people.

Our Innovative Technology Platform

Read More
VEDP2

VEDP: Booming Virginia clusters provide a supply chain blueprint for increasing drug accessibility, affordability

By News

VEDP2Like his fellow Type 1 diabetics, Alec Smith took insulin every day to regulate his blood sugar. Costs to treat his condition topped $1,000 per month, most of that going to insulin, and Alec made the difficult decision to ration his insulin to save money after aging off his mother’s health insurance plan.

Rationing insulin is a delicate process for diabetics. The body’s insulin needs can fluctuate significantly due to changes in diet, exercise, stress, poor sleep, or other medications, and diabetics must constantly monitor their glucose levels even when taking insulin as directed. When a person’s blood sugar gets too high, the body goes into diabetic ketoacidosis, which releases dangerous amounts of acid into the bloodstream and, if left untreated, can result in death — as it unfortunately did for Alec Smith in 2017. His mother, Nicole Smith-Holt, told CBS News, “I think if the price of insulin in 2017 had been $35, Alec would still be alive today.”

Read More
Emergent

Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola

By News

EmergentGAITHERSBURG, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, executed a contract modification for the second option period, valued at approximately $16.7 million, for drug product process and analytical testing validation and long-term stability for Ebanga™ (ansuvimab-zykl). Ebanga™ is indicated for the treatment of infection caused by Zaire Ebola virus.

Read More
Baltimorebiopark

The Baltimore Banner: University of Maryland merges engineering and medicine to turn ideas into companies

By News

BaltimorebioparkIt’s Baltimore’s latest move toward becoming a tech hub

Meredith Cohn – It looks like a rolling suitcase, a mask and some tubes, but for some people who can’t breathe properly, the device will mean freedom.

Those with damaged lungs who are waiting for a transplant, too sick for surgery or just temporarily injured normally have to stay hooked up to bulky machinery in a hospital to stay alive. But a new invention, developed by engineers and doctors from the University of Maryland, means they could soon return home and go about more of their lives.

“Grandpa can come [along] now,” said Dr. Bartley P. Griffith, a professor of transplant surgery in the university’s School of Medicine, about the artificial lung support device he helped create and commercialize before it was bought by Johnson & Johnson.

 

Read More
ARPA H RAPID

ARPA-H RAPID Program: Rare Disease AI/ML for Precision Integrated Diagnostics

By News

ARPA H RAPID*NOTE: Solution Summary due: February 14, 2025
The Big Question  

What if we could end the rare disease diagnostic odyssey?

The Problem  

Collectively, rare diseases are far from rare — more than 10,000 unique conditions affect over 350 million people worldwide, including one in ten Americans. The lengthy diagnostic “odyssey” endured by patients with a rare disease lasts six years on average but can extend for decades. Diagnostic delays stem from multiple factors, including overlapping symptoms, low disease incidence, and limited specialist expertise. It’s estimated that half of all individuals with a rare disease remain undiagnosed or misdiagnosed, leading to inappropriate care, irreversible disease progression, and rising medical costs.  

Read More
Veralox

Veralox Therapeutics Expands Its Pipeline with the Exclusive Option to Acquire Nudge Therapeutics

By News

VeraloxFREDERICK, Md.Jan. 9, 2025 /PRNewswire/ — Veralox Therapeutics, a clinical-stage biotechnology company developing a new class of therapies targeting the 12-lipoxygenase (12-LOX) pathway, announced today that it has entered into an exclusive agreement with Nudge Therapeutics to acquire the company and their preclinical cyclic AMP-GMP (cGAS) inhibitor compounds.  The agreement allows Veralox to continue development of Nudge’s compounds and trigger acquisition of the company upon achievement of downstream milestones. Financial terms were not disclosed.

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.